ArticleCancers2021
Expression of CCRL2 Inhibits Tumor Growth by Concentrating Chemerin and Inhibiting Neoangiogenesis.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Tissue-Specific Chemerin in Atherosclerosis.Biomolecules · 2026Review
- Atypical Chemokine Receptor CCRL2 Shapes Tumor Spheroid Structure and Immune Signaling in Melanoma.Biomolecules · 2025Article
- The biological function and research progress of the adipokine chemerin in tumorigenesis and development.Journal of Cancer · 2025Review
- Atypical chemokine receptors in the immune system.Nature reviews. Immunology · 2024Review
- The Dual Role of Chemerin in Lung Diseases.Cells · 2024Review
- Molecular dynamics of chemotactic signalling orchestrates dental pulp stem cell fibrosis during aging.Frontiers in cell and developmental biology · 2024Article
- Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment.Frontiers in oncology · 2023Article
- Atypical chemokine receptors: emerging therapeutic targets in cancer.Trends in pharmacological sciences · 2022Review
- Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality.Frontiers in immunology · 2022Article
- The Role of Adipokines in Pancreatic Cancer.Frontiers in oncology · 2022Review
- CCRL2 Modulates Physiological and Pathological Angiogenesis During Retinal Development.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
CCRL2 belongs to the G protein-coupled receptor family and is one of the three chemerin receptors. It is considered as a non-signaling receptor, presenting chemerin to cells expressing the functional chemerin receptor ChemR23/CMKLR1 and possibly GPR1. In the present work, we investigate the role played by CCRL2 in mouse cancer models. Loss of function of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.